476results about How to "Increase generation" patented technology

The present invention relates to methods of modulating mammalian stem cell and progenitor cell differentiation. The methods of the invention can be employed to regulate and control the differentiation and maturation of mammalian, particularly human stem cells along specific cell and tissue lineages. The methods of the invention relate to the use of certain small organic molecules to modulate the differentiation of stem or progenitor cell populations along specific cell and tissue lineages, and in particular, to the differentiation of embryonic-like stem cells originating from a postpartum placenta or for the differentiation of early progenitor cells to a granulocytic lineage. Finally, the invention relates to the use of such differentiated stem or progenitor cells in transplantation and other medical treatments.

Disclosed are an ion implantation method capable of dramatically increasing an implantation rate of hydrogen ions into a semiconductor substrate and a method for manufacturing an SOI wafer, in which manufacturing efficiency of the SOI wafer is sufficiently high. When the hydrogen ions are implanted to a predetermined depth of the semiconductor substrate, hydrogen gas is introduced into a chamber where an inner pressure is reduced and a predetermined magnetic field is formed, plasma is generated by introducing a microwave into the magnetic field, hydrogen ion beams containing hydrogen molecule ions is extracted from the plasma, and the hydrogen molecule ions are irradiated and implanted onto the semiconductor substrate. Thus, a throughput in the hydrogen ion implantation is improved, thus making it possible to enhance the manufacturing efficiency of the SOI wafer.

The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1);Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions.

An exhaust emission control apparatus for an internal combustion engine includes a fuel injection valve placed substantially at a midpoint above a combustion chamber of the engine; a piston having an outer cavity formed substantially in a midsection of an upper surface of the piston and an inner cavity formed in a bottom surface of the outer cavity; an ignition plug placed in a region right above the outer cavity; an exhaust purifying catalyst provided in an exhaust passage of the engine; and a controller. This controller is configured to carry out a stratified charge combustion when a temperature rise for the exhaust purifying catalyst is required, by forming air-fuel mixture which is richer than stoichiometric ratio and is able to be ignited by the ignition plug, within the outer cavity and in an area substantially right above the outer cavity, from a fuel injected through the fuel injection valve.

A charged particle guide adapted to be coupled with a charged particle detector, such as a secondary electron detector. The charged particle guide, in one example, comprising two wires extending from the charged particle detector toward a source of charged particles, such as secondary electrons emitted from an IC upon application of a focused ion beam. Upon application of a bias voltage, the charged particle guide introduces a collecting electric field that attracts charged particles and directs the charged particles to the charged particles detector.

A sterilization and decontamination system in which a non-thermal plasma discharge device is disposed upstream of a suspension media (e.g., a filter, electrostatic precipitator, carbon bed). The plasma discharge device generates a plasma that is emitted through apertures (e.g., capillaries or slits) in the primary dielectric. Plasma generated active sterilizing species when exposed to contaminants or undesirable particulate matter is able to deactivate or reduce such matter in contaminated fluid stream and / or on objects. Thus, the undesirable contaminants in the fluid to be treated are first reduced during their exposure to the plasma generated active sterilizing species in the plasma region of the discharge device. Furthermore, the plasma generated active sterilizing species are carried downstream to suspension media and upon contact therewith deactivate the contaminants collected on the suspension media itself. Advantageously, the suspension media may be cleansed in situ. To increase the sterilization efficiency an additive, free or carrier gas (e.g., alcohol, water, dry air) may be injected into the apertures defined in the primary dielectric. These additives increase the concentration of plasma generated active sterilizing agents while reducing the byproduct of generated undesirable ozone pollutants. Downstream of the filter the fluid stream may be further treated by being exposed to a catalyst media or additional suspension media to further reduce the amount of undesirable particulate matter.